Industry News

Join WhatsApp Channel 

Crack GPAT — Prepare for GPAT Online

  • Torrent Pharmaceuticals earn 100 percent equity stake in Zyg Pharma Pvt Ltd, a company engaged in manufacturing various dermatological formulations like creams, ointments, gels, lotions, solutions, for undisclosed price.

  • CyMedica Orthopedics, Inc.,  has commercially launched the CyMedica QB1 System for the treatment of quadriceps muscle atrophy. The CyMedica QB1 System has introduced at the Arthroscopy Association of North American Arthroscopic Society for Sports Medicine (AANA) annual meeting in Los Angeles recently.

  • Biocon, a leading innovation-led bio-pharmaceutical company, has announced satisfactory financial performance during the fourth quarter ended March 2014. Its consolidated net profit, after exceptional income of Rs. 105 crore on account of sale of Syngene shares, increased by 78.2 per cent to Rs. 201.54 crore from Rs. 113.08 crore in the corresponding period of last year. Operating profit jumped 4.7 percent year-on-year to Rs 202 crore for the quarter ended March 2015 from Rs 193 crore in the same quarter last year.Profit before tax and exceptional income also improved by only 4 per cent to Rs. 143.54 crore from Rs. 138.06 crore. EPS moved up to Rs. 10.08 from Rs. 5.76 crore.  Its consolidated net sales increased by 14.9 per cent to Rs. 830.38 crore during the fourth quarter from Rs. 722.59 crore in the same period of last year. Its pharma sales increased by 10.8 per cent to Rs. 594.91 crore from Rs. 536.77 crore and that of contract research & manufacturing services improved by 27.7 per cent to Rs. 248.92 crore from Rs. 194.90 crore.

  • Bosch Packaging Technology, one of the leading suppliers introduce the new granulation unit, GranuLean at Achema 2015 to be held in Germany from June 15 to 19, 2015. It ranges from filling, processing, and packaging technology for piece goods and bulk items in the food, pharmaceutical, and confectionery sectors as well as for health and hygiene products.

  • (Business Wire India); Teva Pharmaceutical Industries Ltd. has announced that an updated investor presentation in connection with its proposed combination with Mylan N.V. is available on the Investor Relations section of the Company’s website and will be filed with the Securities and Exchange Commission (“SEC”).

  • The European Commission has granted marketing authorization in Europe for Sanofi's Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), a next-generation basal insulin for the treatment of type 1 and type 2 diabetes mellitus in adults. Its significant milestone for Sanofi. This gives people with diabetes and their physicians a new option to manage their condition.

  • aTyr Pharma, a biotherapeutics company engaged in the discovery and development of physiocrine-based therapeutics to address rare diseases, announced  that Resolaris has been granted Orphan Drug designation by the US Food and Drug Administration (FDA) for the treatment of facioscapulohumeral muscular dystrophy (FSHD).  Resolaris, an investigational new drug,  is being developed as a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component.

  • Three Indian pharmaceutical companies, namely Alembic Pharmaceuticals, Hetero Labs and Torrent Pharmaceuticals have get the US Food and Drug Administration (FDA) approval for generic versions of Abilify (aripiprazole). Aripiprazole is an atypical antipsychotic drug approved to treat schizophrenia and bipolar disorder.   Teva Pharmaceuticals has also get  similar approval.

     

    [adsense:336x280:8701650588]

Subscribe to Industry News